Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

24.67
+0.84003.52%
Post-market: 24.18-0.4900-1.99%18:29 EDT
Volume:475.37K
Turnover:11.61M
Market Cap:983.39M
PE:70.13
High:24.72
Open:23.91
Low:23.66
Close:23.83
52wk High:27.66
52wk Low:18.80
Shares:39.86M
Float Shares:36.37M
Volume Ratio:0.96
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3518
EPS(LYR):0.1578
ROE:2.05%
ROA:1.48%
PB:1.46
PE(LYR):156.30

Loading ...

Pacira BioSciences CMO Jonathan Slonin Sells 3,040 Shares for $70,619.20

Reuters
·
Aug 19

Pacira Biosciences, Inc. : Truist Securities Reinstates Coverage with Buy Rating; Price Target $30

THOMSON REUTERS
·
Aug 17

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Simply Wall St.
·
Aug 10

Pacira Grants Inducement Equity Awards to New Hires, Including Options Priced at $27.62/share

Reuters
·
Aug 07

Press Release: Pacira BioSciences Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
Aug 07

Pacira Publishes Positive Two-Year Phase 1 Data for PCRX-201 Gene Therapy in Knee Osteoarthritis

Reuters
·
Aug 06

Pacira BioSciences is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Aug 06

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 06

RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating

MT Newswires Live
·
Aug 05

Pacira Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Pacira Q2 FY26 Returns to GAAP Profit of USD 4.7 Million; Revenue Rises 6% to USD 192.4 Million

Reuters
·
Aug 05

Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate

Benzinga Earnings
·
Aug 05

Pacira Biosciences Q2 Revenue USD 192.4 Million Vs. IBES Estimate USD 190.8 Million

Reuters
·
Aug 05

Pacira Biosciences Q2 Cash & Investments USD 251 Million

THOMSON REUTERS
·
Aug 05

Pacira Biosciences Outlook FY Revenue USD 735-760 Million

THOMSON REUTERS
·
Aug 05

Pacira Biosciences Q2 Adjusted Ebitda USD 48.7 Million

THOMSON REUTERS
·
Aug 05

Pacira Biosciences, - Reiterates Fy2026 Exparel Net Product Sales Guidance $600 Mln-$620 Mln

THOMSON REUTERS
·
Aug 05

Will Pacira’s (PCRX) U.S. Manufacturing Shift for PCRX-201 Redefine Its Post-EXPAREL Narrative?

Simply Wall St.
·
Aug 02

Earning Preview: Pacira Pharmaceuticals this quarter’s revenue is expected to increase by 4.26%, and institutional views are bullish

Earnings Agent
·
Jul 29

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

GlobeNewswire
·
Jul 28